Health Care Innovation
Business & Economics
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Blog
Price Transparency Occurs in Markets, Not Government Offices
The wrong model, no matter how hard it is worked, always provides the wrong answer. And, so it is with a bill being considered in Sacramento (SB 17). SB 17 is supposed to address the problem of skyrocketing health care costs by requiring pharmaceutical manufacturers to give 60-day notice for ...
Commentary
Here’s What Single-Payer Advocates Don’t Want You To Know
Single-payer is back on the docket in California. Late last month, Assembly Speaker Anthony Rendon announced that he’d formed a special committee “to develop plans for achieving universal health care in California.” Rendon has been under pressure from progressive activists all summer, ever since he shelved SB 562, a bill ...
Blog
U.S. Pharmaceutical Spending Is Below Average?
For the 30 nations that comprise the Organization for Economic Cooperation and Development (OECD), which promotes policies to improve the well-being of people around the world, pharmaceutical spending comprised, on average, 16.9 percent of total health care spending as of 2015. The OECD defines pharmaceutical spending as the expenditures on ...
Commentary
Piecemeal Repeal Is The Least Bad Obamacare Option
The demise of the Senate’s “skinny” repeal of Obamacare may be a blessing in disguise. Nobody should have mistaken that measure for genuine repeal of the Affordable Care Act — much less for the free-market healthcare reform that most of the GOP has long clamored for. Yet the collapse of ...
Business & Economics
Obstacles To Cutting Edge Cancer Treatments
Disincentives plague the U.S. health care system, driving costs higher and the quality of care lower. Improving health outcomes requires reforms that remove these disincentives. With respect to health insurers, this means returning payers to their proper role of providing effective risk management services to patients. In contrast to other ...
Business & Economics
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
Business & Economics
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Business & Economics
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
Business & Economics
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
Price Controls Will Reduce Innovation and Health Outcomes
Abraham Kaplan famously noted that if you, “give a small boy a hammer, he will find that everything he encounters needs pounding.” Put differently, solving problems requires the right tool, not the convenient tool. Congress should remember this wisdom in its upcoming deliberations regarding the cost of prescription drugs. The ...
Price Transparency Occurs in Markets, Not Government Offices
The wrong model, no matter how hard it is worked, always provides the wrong answer. And, so it is with a bill being considered in Sacramento (SB 17). SB 17 is supposed to address the problem of skyrocketing health care costs by requiring pharmaceutical manufacturers to give 60-day notice for ...
Here’s What Single-Payer Advocates Don’t Want You To Know
Single-payer is back on the docket in California. Late last month, Assembly Speaker Anthony Rendon announced that he’d formed a special committee “to develop plans for achieving universal health care in California.” Rendon has been under pressure from progressive activists all summer, ever since he shelved SB 562, a bill ...
U.S. Pharmaceutical Spending Is Below Average?
For the 30 nations that comprise the Organization for Economic Cooperation and Development (OECD), which promotes policies to improve the well-being of people around the world, pharmaceutical spending comprised, on average, 16.9 percent of total health care spending as of 2015. The OECD defines pharmaceutical spending as the expenditures on ...
Piecemeal Repeal Is The Least Bad Obamacare Option
The demise of the Senate’s “skinny” repeal of Obamacare may be a blessing in disguise. Nobody should have mistaken that measure for genuine repeal of the Affordable Care Act — much less for the free-market healthcare reform that most of the GOP has long clamored for. Yet the collapse of ...
Obstacles To Cutting Edge Cancer Treatments
Disincentives plague the U.S. health care system, driving costs higher and the quality of care lower. Improving health outcomes requires reforms that remove these disincentives. With respect to health insurers, this means returning payers to their proper role of providing effective risk management services to patients. In contrast to other ...
Rising Regulatory Burdens, Declining Health Outcomes
Tweaks do not turn bad regulatory proposals into good ones. Yet, with only minor modifications, Congress is once again considering the CREATES Act (Creating and Restoring Equal Access to Equivalent Samples Act of 2017), and its close cousin, the FAST Act (Fair Access for Safe and Timely Generics Act of ...
New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs
It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States. Recently, U.S. Bernie Sanders has been ...
Drug Importation Will Not Improve Health Care Affordability
The growing problem of health care affordability requires prompt and effective policy solutions. However, just as the wrong medical diagnosis will not cure a patient, and may make the patient even sicker, the wrong policy solution will not address the U.S. health care affordability problem, and may even worsen the ...
New PRI Study Finds That High Prescription Drug Costs Are Not Driving Up U.S. Health Care Costs
A more realistic evaluation of U.S. prescription drug prices shows that high drug prices are not actually driving up health care costs overall, and reflect the higher U.S. health care costs compared to the rest of the world, according to a new report released today by the Pacific Research Institute. ...
